Neurimmune’s technology platform allows the rapid identification of safe, optimized human antibodies and the RTM™ translational medicine process enables the rapid and cost-effective attainment of proof of concept. Neurimmune continues to extend and apply its RTM™ technology platform to identify prime therapeutic antibody candidates. These drugs shall be advanced by the company to the stage where a significant partnership can be formed with biopharmaceutical companies that bring complimentary resources and capabilities to its development and commercialization.
The objective of such collaborations is the identification of human monoclonal antibodies as lead candidates derived from human patients for the treatment of human diseases and the development of such lead candidates as licensed products against such diseases. Neurimmune announced in November 2007 that it entered into an agreement with Biogen Idec Inc., a leading biopharmaceutical company to develop and commercialize novel treatments for Alzheimer’s disease.
Neurimmune maintains a close and highly productive relationship with the University of Zurich, Switzerland, a world-renowned center for neurosciences.